Abstract
Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, with metastasis significantly reducing patient survival. Despite advances in treatment, the molecular mechanisms underlying the progression of colorectal cancer remain poorly understood. Recent studies highlight the role of TPX2 and KIF20A, two proteins involved in cell division, in the development of cancer. TPX2 plays a key role in the assembly of the mitotic spindle, while KIF20A is a member of the kinesin superfamily, which is important for intracellular transport and cytokinesis. Both genes are associated with various types of cancer, but their specific contribution to CRC remains unclear. The aim of this study is to investigate the expression and prognostic significance of TPX2 and KIF20A in CRC through bioinformatic analysis and experimental validation.
Methods: To identify differentially expressed genes (DEGs) in CRC, five publicly available microarray datasets (GSE39582, GSE8671, GSE9348, GSE21510, and GSE44076) were analyzed using the Limma package in R. Functional enrichment analysis of DEGs was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. A protein-protein interaction (PPI) network was created using STRING and visualized using Cytoscape to identify hub genes. Survival analysis of hub genes was performed using the Gene Expression Profiling Interactive Analysis (GEPIA) tool with TCGA data. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic potential of hub genes. Experimental validation was performed on 50 CRC samples using quantitative real-time PCR (qRT-PCR) to measure the expression of TPX2 and KIF20A.
Results: The integrated analysis identified several DEGs significantly involved in CRC, with TPX2 and KIF20A emerging as key hub genes. GO and KEGG analyses showed that these genes are highly associated with cell cycle regulation and mitotic processes. Survival analysis showed that high TPX2 and KIF20A expression correlates with poorer prognosis in colorectal cancer patients. ROC curve analysis confirmed their potential as diagnostic biomarkers. Experimental validation showed significant upregulation of TPX2 and KIF20A in CRC tissues compared to normal controls, supporting the bioinformatic results. Further mechanistic evidence suggests that TPX2 and KIF20A contribute to colorectal cancer progression by promoting cell proliferation and tumor formation. Previous studies also suggest that KIF20A activates the JAK/STAT3 signaling pathway, thereby increasing the aggressiveness of colorectal cancer cells, while TPX2 is associated with chromosomal instability and tumorigenesis. These results suggest that targeting TPX2 and KIF20A may offer new therapeutic opportunities for the treatment of colorectal cancer.
Conclusion: This study highlights the potential role of TPX2 and KIF20A as prognostic biomarkers and therapeutic targets in colorectal cancer. Their significant upregulation in tumor tissue and strong association with poor survival outcomes underscore their importance in colorectal cancer progression. Future research should focus on elucidating the molecular mechanisms underlying their oncogenic role and exploring targeted therapies aimed at modulating their activity to improve outcomes for colorectal cancer patients.
Introduction
Colorectal cancer (CRC) remains a major global health burden despite advancements in treatment1, 2. Approximately 50-60% of CRC patients develop metastases, significantly reducing their 5-year survival rate to around 14%3, 4. The precise genetic mechanisms underlying CRC initiation and progression are still being investigated. Identifying novel gene targets and developing targeted therapies are crucial for improving patient outcomes. Current research focuses on understanding the molecular alterations in CRC and exploring precision medicine approaches to address the disease's heterogeneity and improve treatment effectiveness.
TPX2, a protein encoded on chromosome 20q11.1, is crucial for forming microtubules at kinetochores in mammalian cells5. It acts downstream of Ran-GTP and plays a central role in spindle assembly during cell division. The nominated function of TPX2 includes: in response to Ran-GTP in early mitosis, TPX2 is released and interacts with Aurora A kinase. This interaction directs Aurora A to spindle microtubules, initiating their assembly6, 7. TPX2 shields a critical site on Aurora A, preventing its inactivation and ensuring proper spindle formation. Cells lacking the TPX2/Aurora A complex have abnormal spindles and often fail to divide correctly8, 9. TPX2 expression is tightly controlled throughout the cell cycle, suggesting its potential as a precise marker for tumor cell proliferation. Previous studies have shown that TPX2, a protein involved in cell division, is abnormally expressed in several cancers, including lung, prostate, liver, thyroid, and pancreatic cancer. However, the role of TPX2 in colon cancer has not been explored10.
KIF20A is a newcomer to the kinesin superfamily-611, 12. This kinesin family is known for a special motor domain that allows them to ferry cargo around the cell. They play a vital role in various cellular activities like transporting molecules within the cell, separating chromosomes during cell division, and cell movement, all achieved by interacting with microtubules. Previous research has shown that KIF20A is located near the Golgi apparatus13, 14. KIF20A acts like a molecular truck, using energy (in the form of GTP-bound RAB6A/B) to haul Golgi membranes back from the cell's periphery. Additionally, KIF20A relies on microtubules and its own directional movement to be involved in critical processes like chromosome separation and spindle formation during cell division15, 16. Over the past decade, scientists have found KIF20A expressed in many organs throughout the body. Interestingly, cancer researchers have observed that KIF20A levels are elevated in various cancers, including breast, pancreatic, lung, and bladder cancers. Even more intriguing, evidence suggests KIF20A can promote aggressive behavior in pancreatic and breast cancers17, 18. However, our understanding of KIF20A's role and how it functions in colorectal cancer (CRC) remains limited.
To investigate this, we analyzed publicly accessible gene expression data from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA). Our bioinformatics analysis revealed that TPX2 and KIF20A play a critical role in managing cell cycle progression. These genes are essential for CRC cell proliferation and their ability to form 3D structures that mimic tumors. To validate these results, we investigated the expression of TPX2 and KIF20A in CRC specimens.
Methods
Data Obtained and DEGs Acquired
The GEO is an online repository that allows researchers to store, share, and access functional genomics data, including gene expression data obtained through microarray, next-generation sequencing, and other high-throughput technologies. This platform enables users to search, review, and download data and gene expression profiles. For this study, microarray datasets containing gene expression profiles related to CRC were sourced from the GEO database. A total of five datasets were selected, specifically GSE39582, GSE8671, GSE9348, GSE21510, and GSE44076. These datasets included a total of 748 normal tissue samples and 790 tumor tissue samples.
Integrated Differential Gene Expression Analysis
To analyze gene expression data, we first normalized the raw data using the RMA method and then converted the values to a log2 scale. Next, we used the Limma package in R to identify genes that were expressed at significantly different levels between groups. We considered genes with a log2 fold change greater than 1 and an adjusted P-value less than 0.05 to be differentially expressed. Finally, we combined the lists of differentially expressed genes from all datasets to identify genes that were consistently changed across all experiments.
Functional Enrichment of Selected DEGs
To better understand what the identified genes might do and what biological processes they're involved in, we ran two analyses. Gene Ontology (GO) analysis helped us categorize the genes by their function (what they do), the molecules they interact with (how they do it), and the broader biological processes they contribute to (their role in the cell). KEGG pathway analysis further explored the specific pathways these genes might be involved in, providing a more detailed picture of their biological significance. We used a software package called ClusterProfiler in R along with a visualization tool called shinyGO to perform these analyses. Only pathways and functions with a very high likelihood (p-value less than 0.05) were considered significant.
Constructing PPI Network and Identification of Hub Genes
To explore how the DEGs might work together, we built a network of interacting proteins. We used a website called STRING, which is like a map of protein connections across different organisms. This map includes both known and predicted interactions, showing how proteins might physically touch or work together in certain functions. We focused on interactions with high confidence scores (above 0.9) and excluded genes that didn't connect to others in the network. Next, we used software called Cytoscape to visualize this network of interacting proteins. To find key players within the network, we ran an analysis tool called MCODE. This identified clusters of highly connected genes, which are likely to be working together in important biological processes. Finally, another Cytoscape tool called CytoHubba helped us pinpoint the most central genes in the network, based on their connections to other genes. These central genes, called 'hub genes,' could be particularly important for understanding colorectal cancer.
Survival Analysis of Patients Using Hub Genes
To understand how our identified hub genes affect patient outcomes, we utilized an online tool called GEPIA. This tool lets us analyze data from The Cancer Genome Atlas (TCGA) project and create survival charts (Kaplan-Meier plots) for various genes across different cancers. We focused on colorectal cancer, specifically looking at both colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) patients. We divided the patients into four groups based on their expression levels of the hub genes and compared their overall survival rates. Genes with a statistically significant difference in survival between groups (p-value < 0.05) were considered to have prognostic significance and were chosen for further analysis.
Assessment of Survival-Related Hub Genes Expression Profile by TCGA Data
To further examine the expression patterns of these hub genes, we used the GEPIA online tool to compare their levels in tumor and normal tissues from the TCGA and GTEx datasets. We focused on COAD and READ samples, comparing them to matched normal tissues. Using a strict statistical cutoff, we identified significant differences in the expression of these genes between tumor and normal tissues, confirming their potential role in colon cancer.
ROC Curve Analysis of Hub Genes
To evaluate the diagnostic and prognostic value of the identified hub genes in CRC, we created receiver operating characteristic (ROC) curves using the GSE39582 dataset. ROC curves help us understand how well a test can distinguish between patients with and without CRC. The area under the curve (AUC) is a measure of this ability. By calculating the AUC for each hub gene, we assessed its potential as a biomarker for CRC diagnosis and prognosis.
Sample Collection, RNA Isolation, cDNA Synthesis, Real-Time Quantitative PCR
In short, after the approval of the ethics committee and the complete explanation of the project process to the participants, 50 samples (25 cases and 25 tumor margins as controls) were collected. Then RNA was extracted using a manual protocol and Trizol, and after quantitative and qualitative control of the extracted RNA, cDNA synthesis and RT-qPCR were performed according to previous studies19, 20.
Results
Identification of Integrated DEGs
We analyzed five publicly available gene expression datasets to identify genes that are differentially expressed between colon cancer tissues and normal tissues. After data processing, we found a total of 2,084, 1,387, 2,296, 4,382, and 2,329 differentially expressed genes in the GSE39582, GSE8671, GSE9348, GSE21510, and GSE44076 datasets, respectively. Among these genes, more genes were downregulated than upregulated in most datasets (Supplementary Tables 1-7). A Venn diagram shows the genes that were consistently upregulated or downregulated across all five datasets (Figure 1).
GO and KEGG Pathway Enrichment Analysis of Common DEGs
We analyzed the common differentially expressed genes (DEGs) using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The results are shown in Figure 4. For cellular components (CC) (Figure 4 A), the enriched genes were primarily related to the nucleus, chromosome, and Golgi apparatus. In terms of biological processes (BP) (Figure 4 B), the DEGs were involved in DNA repair, replication, and packaging. For molecular functions (MF) (Figure 4 C), the enriched genes were mainly involved in helicase activity and RNA binding. Additionally, our KEGG pathway analysis (Figure 5) identified seven enriched pathways, including DNA replication, cell cycle, mineral absorption, progesterone-mediated oocyte maturation, microRNAs in cancer, cellular senescence, and metabolic pathways.
Construction of PPI Network and Detection of Hub Genes
In the biological context, cells are integral components of a complex and elaborate network of interactions among biomolecules. Protein-protein interactions (PPIs) play a crucial role in these networks due to their diverse, specific, and adaptive nature. The PPI network derived from STRING, visualized through Cytoscape software, consists of 106 nodes and 1,446 edges, as depicted in Figure 6. Additionally, the most significant 15 hub genes within this network, recognized by the CytoHubba plugin, are detailed in Figure 7.
Prognostic Analysis of Hub Genes
Figure 8 and Figure 9 show how the survival of patients with colon or rectal cancer is related to six key genes: KIF20A, TPX2, DLGAP5, PBK, ARHGAP11B, and RNF146. Our analysis found that changes in these genes can significantly affect how long patients live. For example, changes in DLGAP5 have a strong impact on survival, while changes in PBK have a smaller effect.
Assessment of Survival-Related Hub Genes Expression Profiles by TCGA Data
Our analysis of TCGA data revealed that all genes associated with survival were differentially expressed. Further analysis using GEPIA confirmed the expression patterns of KIF20A and TPX2, aligning with our initial findings. Based on these results, we selected these genes for further investigation (Figure 10).
ROC Curve Analysis
The genes we selected, which were confirmed using additional datasets, showed strong potential as diagnostic and prognostic markers for colorectal cancer. This is based on their high performance in predicting the disease, as measured by the area under the ROC curve (AUC) (Figure 11).
Expression Analysis of KIF20A and TPX2
As shown in Figure 12, after analyzing the results, it is clear that TPX2 and KIF20A had a significant increase in expression in tumor tissue compared to normal tissue.
Discussion
CRC continues to be a major health problem, even with improved diagnostic and treatment methods. KIF20A, a member of the kinesin protein family, has been implicated in various human cancers. Studies have shown that its overexpression is associated with tumorigenesis and cancer progression21, 22. KIF20A plays a crucial role in cell division and organelle dynamics, and its aberrant expression is linked to several malignant tumors, but its role in CRC was previously unclear. This study reveals that KIF20A is overexpressed in CRC compared to normal tissue, at the mRNA levels. This overexpression was associated with advanced stages of the disease, including larger tumor size, lymph node involvement, and distant metastasis. Importantly, high KIF20A expression is associated with poor prognosis in CRC patients, suggesting its potential as a prognostic biomarker. Further investigations demonstrated that KIF20A promotes the aggressive behavior of CRC cells by enhancing their proliferation and ability to form colonies.
A study explored the relationship between KIF20A and the JAK/STAT3 signaling pathway, a known oncogenic pathway involved in cancer development. Results suggest that KIF20A may promote CRC cell growth and migration by activating this pathway. This finding highlights the potential of targeting KIF20A as a therapeutic strategy for CRC. Targeting KIF20A, particularly through the JAK/STAT3 pathway, may offer new therapeutic avenues for CRC treatment23. Further research is needed to fully elucidate its role in CRC and explore its potential as a therapeutic target.
A recent study by Wu et al. highlighted the importance of the KIF20A protein in colorectal cancer (CRC). They found that KIF20A levels were elevated in both animal models and cell cultures of CRC. When KIF20A was experimentally reduced (knocked down) in SW480 cells, these cells grew slower, migrated less, and were more likely to die. Conversely, increasing KIF20A levels (overexpression) in HT-29 cells had the opposite effect. Furthermore, the study showed that KIF20A affects cellular metabolism. Reducing KIF20A decreased the production of pyruvate, lactate, and ATP, while increasing KIF20A boosted these metabolic markers, indicating a shift towards aerobic glycolysis (the Warburg effect). Western blot analysis revealed that KIF20A influences the levels of several proteins involved in cancer metabolism, including c-Myc, HIF-1α, PKM2, and LDHA. Rescue experiments further confirmed that KIF20A promotes the Warburg effect through its interaction with c-Myc and HIF-1α. These findings suggest that KIF20A plays a critical role in CRC progression by regulating both cell growth and metabolism. Targeting KIF20A could potentially be a promising strategy for treating CRC24.
In a study by Li Cheng Zhang et al., researchers investigated the role of a circular RNA called Circ_0084188 in colorectal cancer (CRC). They found that Circ_0084188 was elevated in CRC cells, while a microRNA called miR-769-5p was reduced. When Circ_0084188 was experimentally decreased, CRC cells grew slower, migrated less, and were more likely to die. These effects were reversed when miR-769-5p was also reduced, suggesting that Circ_0084188 acts by regulating miR-769-5p. Further analysis revealed that KLF20A, a protein involved in cell growth and migration, is a direct target of miR-769-5p. By sponging to miR-769-5p, Circ_0084188 effectively increases the levels of KLF20A. This ultimately promotes the growth and spread of CRC cells. In animal models, reducing Circ_0084188 slowed the growth of CRC tumors. These findings suggest that targeting Circ_0084188 or its downstream target KLF20A might be potential strategies for treating CRC25.
Yang and colleagues discovered that in colorectal cancer cells, the overproduction of KIF20A/NUAK1 can protect against the cell death caused by oxaliplatin. This occurs by preventing oxidative stress and a process called ferroptosis. The researchers found that KIF20A/NUAK1 activates the GSK3β/Nrf2 pathway, which helps the cells resist chemotherapy. These findings suggest that targeting KIF20A/NUAK1 might be a promising strategy for overcoming chemotherapy resistance in colorectal cancer26.
Tumorigenesis is a condition marked by cells dividing uncontrollably and forming tumors. This process is linked to changes in genes or proteins that normally keep cell growth, death, and DNA integrity in check. This often stems from changes in genes or proteins that regulate cell division, cell death, and maintaining the integrity of the genomic stability27, 28, 29. To develop effective treatments, identifying these genes and their protein products involved in the molecular steps leading to cancer is crucial. Our research focused on TPX2, a potential marker implicated in colon cancer development. We found that TPX2 levels were significantly elevated in CRC. This suggests that TPX2 might play a role in colon cancer progression and could be a valuable target for future therapeutic strategies.
A research team led by Ping Wei identified TPX2 protein overexpression in metastatic colon cancer lesions. Higher TPX2 levels correlated with worse patient outcomes, including metastasis and survival. In lab experiments, suppressing TPX2 expression reduced colon cancer cell growth, migration, and invasion. These findings suggest TPX2 as a potential biomarker for prognosis and a target for developing colon cancer therapies30.
A study evaluated TPX2 gene copy number, expression, and potential as a therapeutic target in pancreatic cancer. Findings show increased copy number and expression of TPX2 were observed in pancreatic cancer cell lines and tumor tissues compared to healthy controls. Silencing TPX2 using small interfering RNAs (siRNAs) in cancer cells resulted in reduced cell growth, apoptosis, and inhibited tumor growth in lab models and mice. TPX2 knockdown also increased the effectiveness of paclitaxel, a chemotherapy drug. In conclusion, TPX2 shows promise as a potential therapeutic target for pancreatic cancer10.
A study by Y. Takahashi et al. utilized a combination of computer modeling (in silico analyses) and laboratory experiments (in vitro experiments) to identify two genes, AURKA and TPX2, as potential co-regulators of MYC in colorectal cancer cells. The research suggests that AURKA and TPX2 might collaborate with MYC, a well-known oncogene (cancer-promoting gene), to drive tumor development in colorectal cancers. Both AURKA and TPX2 reside on chromosome 20q, a region frequently amplified (increased copy number) across various cancers. The study revealed a high prevalence of co-amplification between the MYC locus (8q24) and chromosome 20q in diverse cancer types. While the exact mechanisms behind this co-amplification remain unclear, the research suggests that it might be driven by natural selection favoring the cooperative oncogenic activity of MYC with these two genes located on chromosome 20q. This work sheds light on the potential role of AURKA and TPX2 as co-regulators of MYC in colorectal cancer. Understanding the underlying mechanisms of their co-amplification and cooperative function with MYC could provide new targets for therapeutic strategies in MYC-driven cancers31.
A study investigated the potential of targeting two genes, TPX2 and TTK, for treating CRC. The study confirms, based on existing research, that TPX2 and TTK are crucial genes for CRC development. Analysis of patient tumors revealed a complex network involving both genes, suggesting their coordinated role in CRC progression. When researchers inhibited TPX2 and TTK function, it significantly reduced CRC cell proliferation, their ability to form colonies, and their growth in 3D models mimicking tumor environments. Further analysis revealed that specifically depleting TPX2 and TTK impaired cell cycle progression in CRC cells, particularly under 3D culture conditions. This suggests that cell cycle regulation is a critical pathway affected by the loss of these genes. The study found that elevated levels of TPX2 and TTK correlated with a more aggressive tumor state in patient samples. This finding strengthens the evidence for the oncogenic role of the TPX2/TTK network in CRC development. Analyzing gene-drug interactions within the TPX2/TTK network identified several promising targets that could be potentially inhibited by existing drugs. Overall, this study provides compelling evidence for targeting the TPX2/TTK network as a promising therapeutic strategy for colorectal cancer. The identification of multiple actionable targets and potential drug interactions warrants further investigation to develop effective CRC treatments32.
Another research study examined the expression levels of two molecules, miR-485-3p and TPX2, in CRC tissues. Their findings indicated a significant downregulation of miR-485-3p, while TPX2 exhibited upregulation in CRC tissues compared to healthy controls. Based on these observations, the study suggests that miR-485-3p might function as a tumor suppressor gene in CRC33.
Despite the results, this study had significant shortcomings, such as a small sample size, no experiments to determine whether these genes actually affect cell proliferation, migration, invasion, or the ability of tumor cells to form 3D structures, the lack of the use of RNA sequencing data (RNA-seq), the lack of investigation of protein expression, and some data sets compare tumor tissue with normal tissue from healthy individuals, while others use adjacent non-tumor tissue from the same patients as controls.
Conclusion
TPX2 and KIF20A, previously linked to cancer cell growth and tumor formation, are also implicated in metastasis due to their tight regulation of the cell cycle. Invasion and metastasis are hallmarks of colon cancer and significantly impact patient outcomes. Identifying the molecular mechanisms underlying these processes is crucial for developing targeted therapies. Our bioinformatics analysis and RTqPCR results revealed upregulation of TPX2 and KIF20A in colon cancer cells. These findings suggest that TPX2 and KIF20A play critical roles in colon cancer invasion and metastasis, making them promising targets for new treatments. Our data also emphasize the importance of TPX2 and KIF20A in regulating cell cycle processes and driving colon cancer growth.
Abbreviations
AUC: Area Under the Curve, AURKA: Aurora Kinase A, cDNA: Complementary DNA, COAD: Colon Adenocarcinoma, CRC: Colorectal Cancer, DEGs: Differentially Expressed Genes, GEO: Gene Expression Omnibus, GEPIA: Gene Expression Profiling Interactive Analysis, GO: Gene Ontology, GSK3β: Glycogen Synthase Kinase 3 Beta, GTEx: Genotype-Tissue Expression, HIF:1α: Hypoxia-Inducible Factor 1-alpha, JAK/STAT3: Janus Kinase/Signal Transducer and Activator of Transcription 3, KEGG: Kyoto Encyclopedia of Genes and Genomes, KIF20A: Kinesin Family Member 20A, KLF20A: Krüppel:Like Factor 20A, LDHA: Lactate Dehydrogenase A, MCODE: Molecular Complex Detection, miR-485-3p: MicroRNA 485-3p, Nrf2: Nuclear Factor Erythroid 2–Related Factor 2, NUAK1: NUAK Family Kinase 1, PKM2: Pyruvate Kinase M2, PPI: Protein-Protein Interaction, READ: Rectal Adenocarcinoma, RNA-seq: RNA Sequencing, ROC: Receiver Operating Characteristic, RMA: Robust Multi:array Average, RT-qPCR: Reverse Transcription Quantitative Polymerase Chain Reaction, STRING: Search Tool for the Retrieval of Interacting Genes/Proteins, TCGA: The Cancer Genome Atlas, TPX2: Targeting Protein for Xklp2, TTK: Threonine Tyrosine Kinase.
Acknowledgments
The authors would like to thank to Ms. Mozhdeh and Dr. hajati, for their valuable support.
Author’s contributions
F.GH and M.T: performing the main steps of essay and writing the manuscript. H.M, E.B, S.K, A.J: Collecting the samples and helping to perform RNA extraction, qPCR, Analysis of results and doing statistical tests. M.D: Head of team and monitoring and fixing technical errors during all steps of the study. All authors read and approved the final manuscript.
Funding
None.
Availability of data and materials
Data and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study protocol was approved by the Institutional Ethics Committee of Shahid Sadoughi University of Medical Sciences of Yazd (approval number IR.SSU.MEDICINE.REC.1402.235). Prior to tissue sample collection, written informed consent was obtained from all participants.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
-
Hoseini
S.H.,
Enayati
P.,
Nazari
M.,
Babakhanzadeh
E.,
Rastgoo
M.,
Sohrabi
N.B.,
Biomarker Profile of Colorectal Cancer: Current Findings and Future Perspective. Journal of Gastrointestinal Cancer.
2024;
55
(2)
:
497-510
.
View Article PubMed Google Scholar -
Mollanoori
H.,
Ghelmani
Y.,
Hassani
B.,
Dehghani
M.,
Integrated whole transcriptome profiling revealed a convoluted circular RNA-based competing endogenous RNAs regulatory network in colorectal cancer. Scientific Reports.
2024;
14
(1)
:
91
.
View Article Google Scholar -
J.M. Davies,
R.M. Goldberg,
Treatment of metastatic colorectal cancer. InSeminars in oncology.
2011;
38
(4)
:
552-560
.
View Article Google Scholar -
Engstrand
J.,
Nilsson
H.,
Strömberg
C.,
Jonas
E.,
Freedman
J.,
Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer.
2018;
18
(1)
:
78
.
View Article PubMed Google Scholar -
Wittmann
T.,
Boleti
H.,
Antony
C.,
Karsenti
E.,
Vernos
I.,
Localization of the kinesin-like protein Xklp2 to spindle poles requires a leucine zipper, a microtubule-associated protein, and dynein. The Journal of Cell Biology.
1998;
143
(3)
:
673-85
.
View Article PubMed Google Scholar -
Tulu
U.S.,
Fagerstrom
C.,
Ferenz
N.P.,
Wadsworth
P.,
Molecular requirements for kinetochore-associated microtubule formation in mammalian cells. Current Biology.
2006;
16
(5)
:
536-41
.
View Article PubMed Google Scholar -
Gruss
O.J.,
Wittmann
M.,
Yokoyama
H.,
Pepperkok
R.,
Kufer
T.,
Silljé
H.,
Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells. Nature Cell Biology.
2002;
4
(11)
:
871-9
.
View Article PubMed Google Scholar -
Gruss
O.J.,
Vernos
I.,
The mechanism of spindle assembly: functions of Ran and its target TPX2. The Journal of Cell Biology.
2004;
166
(7)
:
949-55
.
View Article PubMed Google Scholar -
Gruss
O.J.,
Carazo-Salas
R.E.,
Schatz
C.A.,
Guarguaglini
G.,
Kast
J.,
Wilm
M.,
Ran induces spindle assembly by reversing the inhibitory effect of importin α on TPX2 activity. Cell.
2001;
104
(1)
:
83-93
.
View Article PubMed Google Scholar -
Warner
S.L.,
Stephens
B.J.,
Nwokenkwo
S.,
Hostetter
G.,
Sugeng
A.,
Hidalgo
M.,
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clinical Cancer Research.
2009;
15
(21)
:
6519-28
.
View Article PubMed Google Scholar -
Verhey
K.J.,
Hammond
J.W.,
Traffic control: regulation of kinesin motors. Nature Reviews. Molecular Cell Biology.
2009;
10
(11)
:
765-77
.
View Article PubMed Google Scholar -
Hirokawa
N.,
Noda
Y.,
Tanaka
Y.,
Niwa
S.,
Kinesin superfamily motor proteins and intracellular transport. Nature Reviews. Molecular Cell Biology.
2009;
10
(10)
:
682-96
.
View Article PubMed Google Scholar -
Lai
F.,
Fernald
A.A.,
Zhao
N.,
Le Beau
M.M.,
cDNA cloning, expression pattern, genomic structure and chromosomal location of RAB6KIFL, a human kinesin-like gene. Gene.
2000;
248
(1-2)
:
117-25
.
View Article PubMed Google Scholar -
Imai
K.,
Hirata
S.,
Irie
A.,
Senju
S.,
Ikuta
Y.,
Yokomine
K.,
Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. British Journal of Cancer.
2011;
104
(2)
:
300-7
.
View Article PubMed Google Scholar -
Kikuchi
T.,
Daigo
Y.,
Katagiri
T.,
Tsunoda
T.,
Okada
K.,
Kakiuchi
S.,
Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene.
2003;
22
(14)
:
2192-205
.
View Article PubMed Google Scholar -
Ho
J.R.,
Chapeaublanc
E.,
Kirkwood
L.,
Nicolle
R.,
Benhamou
S.,
Lebret
T.,
Deregulation of Rab and Rab effector genes in bladder cancer. PLoS One.
2012;
7
(6)
:
e39469
.
View Article PubMed Google Scholar -
Stangel
D.,
Erkan
M.,
Buchholz
M.,
Gress
T.,
Michalski
C.,
Raulefs
S.,
Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. Journal of surgical research.
2015;
197
(1)
:
91-100
.
View Article Google Scholar -
Khongkow
P.,
Gomes
A.R.,
Gong
C.,
Man
E.P.,
Tsang
J.W.,
Zhao
F.,
Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene.
2016;
35
(8)
:
990-1002
.
View Article PubMed Google Scholar -
Babakhanzadeh
E.,
Khodadadian
A.,
Rostami
S.,
Alipourfard
I.,
Aghaei
M.,
Nazari
M.,
Testicular expression of TDRD1, TDRD5, TDRD9 and TDRD12 in azoospermia. BMC Medical Genetics.
2020;
21
(1)
:
33
.
View Article PubMed Google Scholar -
Babakhanzadeh
E.,
Khodadadian
A.,
Nazari
M.,
Dehghan Tezerjani
M.,
Aghaei
S.M.,
Ghasemifar
S.,
Deficient expression of DGCR8 in human testis is related to spermatogenesis dysfunction, especially in meiosis I. International Journal of General Medicine.
2020;
13
:
185-92
.
View Article PubMed Google Scholar -
Li
X.,
Shu
K.,
Wang
Z.,
Ding
D.,
Prognostic significance of KIF2A and KIF20A expression in human cancer: A systematic review and meta-analysis. Medicine.
2019;
98
(46)
:
e18040
.
View Article PubMed Google Scholar -
Sheng
Y.,
Wang
W.,
Hong
B.,
Jiang
X.,
Sun
R.,
Yan
Q.,
Upregulation of KIF20A correlates with poor prognosis in gastric cancer. Cancer Management and Research.
2018;
10
:
6205-16
.
View Article PubMed Google Scholar -
Xiong
M.,
Zhuang
K.,
Luo
Y.,
Lai
Q.,
Luo
X.,
Fang
Y.,
KIF20A promotes cellular malignant behavior and enhances resistance to chemotherapy in colorectal cancer through regulation of the JAK/STAT3 signaling pathway. Aging (Albany NY).
2019;
11
(24)
:
11905-21
.
View Article PubMed Google Scholar -
Wu
M.,
Wu
X.,
Han
J.,
KIF20A Promotes CRC Progression and the Warburg Effect through the C-Myc/HIF-1α Axis. Protein and Peptide Letters.
2024;
31
(2)
:
107-15
.
View Article PubMed Google Scholar -
Zhang
L.,
Song
W.,
Shi
J.,
Chen
Y.,
Circ_0084188 Regulates the progression of colorectal cancer through the miR-769-5p/KIF20A axis. Biochemical Genetics.
2023;
61
(5)
:
1727-44
.
View Article PubMed Google Scholar -
Yang
C.,
Zhang
Y.,
Lin
S.,
Liu
Y.,
Li
W.,
Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging (Albany NY).
2021;
13
(10)
:
13515-34
.
View Article PubMed Google Scholar -
Dzobo
K.,
Senthebane
D.A.,
Dandara
C.,
The tumor microenvironment in tumorigenesis and therapy resistance revisited. Cancers (Basel).
2023;
15
(2)
:
376
.
View Article PubMed Google Scholar -
Shin
D.,
Cho
K.H.,
Critical transition and reversion of tumorigenesis. Experimental {&}amp; Molecular Medicine.
2023;
55
(4)
:
692-705
.
View Article PubMed Google Scholar -
Dzobo
K.,
Dandara
C.,
The extracellular matrix: its composition, function, remodeling, and role in tumorigenesis. Biomimetics (Basel, Switzerland).
2023;
8
(2)
:
146
.
View Article PubMed Google Scholar -
Wei
P.,
Zhang
N.,
Xu
Y.,
Li
X.,
Shi
D.,
Wang
Y.,
TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. Journal of Translational Medicine.
2013;
11
(1)
:
313
.
View Article PubMed Google Scholar -
Takahashi
Y.,
Sheridan
P.,
Niida
A.,
Sawada
G.,
Uchi
R.,
Mizuno
H.,
The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
2015;
26
(5)
:
935-42
.
View Article PubMed Google Scholar -
Shaath
H.,
Vishnubalaji
R.,
Elango
R.,
Velayutham
D.,
Jithesh
P.V.,
Alajez
N.M.,
Therapeutic targeting of the TPX2/TTK network in colorectal cancer. Cell Communication and Signaling.
2023;
21
(1)
:
265
.
View Article PubMed Google Scholar -
Taherdangkoo
K.,
Nezhad
S.R. Kazemi,
Hajjari
M.R.,
Birgani
M. Tahmasebi,
miR-485-3p suppresses colorectal cancer via targeting TPX2. Bratislava Medical Journal/Bratislavské Lekárske Listy.
2020;
121
(4)
:
302-7
.
View Article PubMed Google Scholar
Comments

Downloads
Article Details
Volume & Issue : Vol 12 No 2 (2025)
Page No.: 7168-7183
Published on: 2025-02-28
Citations
Copyrights & License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Search Panel
Pubmed
Google Scholar
Pubmed
Google Scholar
Pubmed
Google Scholar
Pubmed
Google Scholar
Pubmed
Google Scholar
Pubmed
Google Scholar
Pubmed
Search for this article in:
Google Scholar
Researchgate
- HTML viewed - 0 times
- PDF downloaded - 0 times
- XML downloaded - 0 times
- Supplement Table downloaded - 0 times